

U.S. DEPARTMENT OF COMMERCE PATENT & TRADEMARK OFFICE

B/O Form PTO-1390		Transmittal Letter to the United States Designated/Elected Office (DO/EO/US) Concerning a Filing Under 35 USC 371		Attorney's Docket Number DAVI3002/REF	
International Application Number PCT/GB99/03813		International Filing Date 16 November 1999		U.S. Application Number (if known) 09/831371	
Title of Invention CELLS, CULTURE METHODS, AND THEIR USE IN AUTOLOGOUS TRANSPLANTATION THERAPY		Priority Date Claimed 16 November 1998			
Applicant(s) for DO/EO/US Alison DAVIES					

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items under 35 USC 371:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 USC 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 USC 371.
3. ☒ This express request to begin national examination procedures (35 USC 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 USC 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed 35 USC 371(c)(2).
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 USC 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 USC 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 USC 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 USC 371(c)(4)). (☒ Executed ☐ Unexecuted)
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 USC 371(c)(5)).

Items 11 to 16 below concern other document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
 - ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☐ Other items or information:

Application Number (if Known) 09/831371		International Application Number PCT/GB99/03813		Attorney's Docket Number DAVI3002/REF	
				Calculations	PTO USE ONLY
17. The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)-(5)): <input checked="" type="checkbox"/> Search report has been prepared by the EPO or JPO \$860.00 <input type="checkbox"/> International Preliminary Examination Fee paid to USPTO (37 CFR 1.482) \$690.00 <input type="checkbox"/> No International Preliminary Examination Fee paid to USPTO (37 CFR 1.482) but International Search Fee paid to USPTO (37 CFR 1.445(a)(2)) \$710.00 <input type="checkbox"/> Neither International Preliminary Examination Fee (37 CFR 1.482) nor International Search Fee (37 CFR 1.445(a)(2)) paid to USPTO \$1000.00 <input type="checkbox"/> International Preliminary Examination Fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00				\$860.00	
ENTER APPROPRIATE BASIC FEE AMOUNT				\$ 860.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).					
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total Claims	19 -20 =	0	× \$18.00	\$ 0.00	
Independent Claims	3 -3 =	0	× \$80.00	\$ 0.00	
Multiple Dependent Claims (if applicable)			+ \$270.00		
TOTAL OF ABOVE CALCULATIONS				\$ 860.00	
Reduction by ½ for filing by small entity, if applicable. Small Entity Status is asserted pursuant to 37 CFR 1.27 for this application.				\$ 430.00	
SUBTOTAL				\$ 430.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).					
TOTAL NATIONAL FEE					
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property.				\$ 40.00	
TOTAL FEES ENCLOSED				\$ 470.00	
Amount to be:				Refunded:	
				Charged:	

- a. ☒ A check in the amount of \$470.00 to cover the fees is enclosed.
- b. ☐ Please charge my Deposit Account Number 02-0200 in the amount of \$_____ to cover the above fees.
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account Number 02-0200. A duplicate copy of this sheet is enclosed.

Note: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

BACON & THOMAS, PLLC
 625 SLATERS LANE - FOURTH FLOOR
 ALEXANDRIA, VIRGINIA 223124-1176
 (703) 683-0500

DATE: May 16, 2001

Respectfully submitted,

Richard E. Fichter

Richard E. Fichter
 Attorney for Applicant
 Registration Number: 26,382

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Alison DAVIES

U.S. National Phase of PCT/GB99/03813

Entry papers filed herewith May 16, 2001

For: CELLS, CULTURE METHODS, AND THEIR USE IN
AUTOLOGOUS TRANSPLANTATION THERAPY

Attention: PCT OFFICE

**PRELIMINARY AMENDMENT
AND INFORMATION DISCLOSURE STATEMENT**Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The present application is the U.S. national phase of international application number PCT/GB99/03813. The following amendments pertain to the claims as amended.

Please note that the amended page 10 attached to the International Preliminary Examination Report (Annexes) and submitted herewith, have replaced the originally filed page 10 of the application. The claims to be examined and amended by this preliminary amendment are found on amended pages 43-45.

Please amend the above-identified application as follows:

IN THE SPECIFICATION:

Please add the attached ABSTRACT OF THE DISCLOSURE to the application.

IN THE CLAIMS:

Please cancel claim 1 without prejudice or disclaimer.

Please replace claims 4-12 with the following amended claims 4-12.

4(Amended). A method as claimed in claim 2, wherein said host cells are harvested from said host organism at a stage when there is no direct prediction, suggestion or suspicion that said disease or disorder may develop.

5(Amended). A method as claimed in claim 2, wherein said host organism is a human.

6(Amended). A method as claimed in claim 2, wherein said host organism is juvenile, adolescent or adult, at the same time the cells are obtained.

7(Amended). A method as claimed in claim 2, wherein the immune system of said host organism is mature, at the time the cells are obtained.

8(Amended). A method as claimed in claim 2, wherein the immune system of said host organism is uncompromised, at the time the cells are obtained.

9(Amended). A method as claimed in claim 2, wherein said lymphocyte cells are T-lymphocyte cells.

10(Amended). A method as claimed in claim 3, wherein said therapy is therapy of a chronic condition.

11(Amended). A method as claimed in claim 2, wherein said therapy is cancer therapy.

12(Amended). A method as claimed in claim 2, wherein said therapy is for HIV infection or AIDS.

Please replace claims 14-16 with amended claims 14-16 as follows.

14(Amended). A method as claimed in claim 2, wherein said host cell population is maintained in a state of dormancy.

15(Amended). A method as claimed in claim 2, wherein said host cell population comprises a genetically modified cell.

16(Amended). A method as claimed in claim 2, wherein, after removal from the host and before transplantation, said host cell population is stored by freezing the cells.

Please replace claims 19-20 with amended claims 19-20 as follows.

19(Amended). A method as claimed in claim 17 wherein said lymphocyte cells are T-lymphocyte cells.

20(Amended). A dormant lymphocyte cell population obtained by the method of claim 17.

REMARKS

Applicants have amended the claims in order to reduce the initial filing fee by deleting the multiple dependent claims from the application. Applicants retain the right to reintroduce any subject matter canceled by the present Amendment at any time during the prosecution of this application or any further application claiming benefit of this application.

Applicants have amended the application to substitute the originally filed pages 10 and 43-45 with the amended pages 10 and 43-45 attached to the International Preliminary Examiner Report (Annexes). Also, an Abstract of the Disclosure has been added to the application.

Applicants are submitting herewith a copy of the Search Report which issued on International Application No. PCT/GB99/03813, of which the present application is the U.S. national phase. All of the publications cited in the International Search Report are listed on the attached Form PTO-1449. It is Applicants' understanding that, under the procedures of the PCT, copies of the cited publications will have been supplied to the U.S. Patent Office by the International Bureau. However, the Examiner is invited to contact the undersigned attorney if additional copies are necessary or would facilitate examination of the present application.

Otherwise, the Examiner is respectfully requested to return an initialed and dated copy of the attached Form PTO-1449 to confirm that all publications listed thereon have been considered and made officially of record in the file of this application.

Applicants understand that, under the procedures of the PCT, a copy of the priority document (GB 9825096.2, filed 16 November 1998) will have been supplied to the U.S. Patent Office pursuant to Rule 17 of the PCT Regulations. It is therefore respectfully requested that the first Official Action in the present application contain an indication that the appropriate priority document is in the file of this application.

In view of the above amendments, an early action on the application is now in order and is most respectfully requested.

Respectfully submitted,
BACON & THOMAS, PLLC

By: Richard E. Fichter
RICHARD E. FICHTER
Registration No. 26,382

625 Slaters Lane - 4th Floor
Alexandria, Virginia 22314
Phone: (703) 683-0500
Facsimile: (703) 683-1080

REF:kdd
PA01.wpd

DATE: May 16, 2001

Marked-Up Version Showing Changes Made

IN THE CLAIMS:

4(Amended). A [use,] method [or composition] as claimed in [any one of claims 1 to 3] claim 2, wherein said host cells are harvested from said host organism at a stage when there is no direct prediction, suggestion or suspicion that said disease or disorder may develop.

5(Amended). A [use,] method [or composition] as claimed in [any one of claims 1 to 4] claim 2, wherein said host organism is a human.

6(Amended). A [use,] method [or composition] as claimed in [any one of claims 1 to 5] claim 2, wherein said host organism is juvenile, adolescent or adult, at the same time the cells are obtained.

7(Amended). A [use,] method [or composition] as claimed in [any one of claims 1 to 6] claim 2, wherein the immune system of said host organism is mature, at the time the cells are obtained.

8(Amended). A [use,] method [or composition] as claimed in [any one of claims 1 to 7] claim 2, wherein the immune system of said host organism is uncompromised, at the time the cells are obtained.

9(Amended). A [use,] method [or composition] as claimed in [any one of claims 1 to 8] claim 2, wherein said lymphocyte cells are T-lymphocyte cells.

10(Amended). A [use,] method [or composition] as claimed in [any one of claims 1 to 9] claim 3, wherein said therapy is therapy of a chronic condition.

11(Amended). A [use,] method [or composition] as claimed in [any one of claims 1 to 9] claim 2, wherein said therapy is cancer therapy.

12(Amended). A [use,] method [or composition] as claimed in [any one of claims 1 to 9] claim 2, wherein said therapy is for HIV infection or AIDS.

14(Amended). A [use,] method [or composition] as claimed in [any one of claims 1 to 13] claim 2, wherein said host cell population is maintained in a state of dormancy.

15(Amended). A [use,] method [or composition] as claimed in [any one of claims 1 to 14] claim 2, wherein said host cell population comprises a genetically modified cell.

16(Amended). A [use,] method [or composition] as claimed in [any one of claims 1 to 15] claim 2, wherein, after removal from the host and before transplantation, said host cell population is stored by freezing the cells.

19(Amended). A method as claimed in claim 17 [or claim 18] wherein said lymphocyte cells are T-lymphocyte cells.

20(Amended). A dormant lymphocyte cell population obtained by the method of [any one of claims 17 to 19] claim 17.

- 10 -

organism.

5 A still further aspect of the invention provides use of a host cell population obtained from a non-diseased host organism for subsequent autologous transplantation therapy of said host organism.

10 The host organism may be any eukaryotic organism, but preferably will be an animal, more preferably a mammal, and most preferably a human. Other representative host organisms include rats, mice, pigs, dogs, cats, sheep, horses and cattle.

15 The term "non-diseased" is used herein to describe a state in which the host organism is not suffering from, or demonstrating symptoms of, the disease or disorder, which it is subsequently intended to treat by the transplantation procedure.

20 Furthermore, in certain embodiments of the invention, the host organism is preferably not predisposed to, or at risk from, any particular disease or disorder e.g. preferably not exhibiting any symptoms or manifestations predictive of a subsequent disease or disorder.

25 Likewise, the host organism is preferably not suffering from any injuries or damage which may give rise to an anticipated or expected condition. A major idea or concept behind the present invention is to harvest or collect the host cells from the host organism at a stage
30 when there is no direct prediction, suggestion, or suspicion that a particular disorder or disease may develop, for use against a future possible or unpredicted event, or an event which may occur simply by

AMENDED SHEET

EMPfangszeit 14. FEB. 17:47

Ausdruckzeit 15 FEB 9.11

- 43 -

Claims

1. Use of a host cell population of mature, healthy lymphocyte cells obtained from blood of a non-diseased host organism for the preparation of a cell composition for use in subsequent autologous therapeutic transplantation therapy of a disease or disorder of said host organism, wherein the cells are obtained from the host organism before the disease or disorder develops or manifests itself.

2. A method of autologous therapeutic transplantation therapy of a disease or disorder of a host organism, said method comprising transplanting a host organism with a cell composition prepared from a host cell population of mature, healthy lymphocyte cells obtained from blood of said host organism when non-diseased, wherein the cells are obtained from the host organism before the disease or disorder develops or manifests itself.

3. A composition comprising a host cell population of mature healthy lymphocyte cells obtained from blood of a non-diseased host organism for use in subsequent autologous therapeutic transplantation therapy of a disease or disorder of said host organism, wherein the cells are obtained from the host organism before the disease or disorder develops or manifests itself.

4. A use, method or composition as claimed in any one of claims 1 to 3, wherein said host cells are harvested from said host organism at a stage when there is no direct prediction, suggestion or suspicion that said disease or disorder may develop.

5. A use, method or composition as claimed in any one of claims 1 to 4, wherein said host organism is a human.

- 44 -

- 5 6. A use, method or composition as claimed in any one of claims 1 to 5, wherein said host organism is juvenile, adolescent or adult, at the time the cells are obtained.
7. A use, method or composition as claimed in any one of claims 1 to 6, wherein the immune system of said host organism is mature, at the time the cells are obtained.
- 10 8. A use, method or composition as claimed in any one of claims 1 to 7, wherein the immune system of said host organism is uncompromised, at the time the cells are obtained.
- 15 9. A use, method or composition as claimed in any one of claims 1 to 8, wherein said lymphocyte cells are T-lymphocyte cells.
- 20 10. A use, method or composition as claimed in any one of claims 1 to 9, wherein said therapy is therapy of a chronic condition.
- 25 11. A use, method or composition as claimed in any one of claims 1 to 9, wherein said therapy is cancer therapy.
- 30 12. A use, method or composition as claimed in any one of claims 1 to 9, wherein said therapy is for HIV infection or AIDS.
- 35 13. A use, method or composition as claimed in claim 12, wherein said host cell population comprises CD4⁺ cells.
14. A use, method or composition as claimed in any one of claims 1 to 13, wherein said host cell population is maintained in a state of dormancy.

- 45 -

15. A use, method or composition as claimed in any one of claims 1 to 14, wherein said host cell population comprises a genetically modified cell.

5 16. A use, method or composition as claimed in any one of claims 1 to 15 wherein, after removal from the host and before transplantation, said host cell population is stored by freezing the cells.

10 17. A method of making and/or maintaining lymphocyte cells dormant, said method comprising freezing said lymphocyte cells to a temperature at or below -269°C .

15 18. A method as claimed in claim 17 wherein said lymphocyte cells are obtained from blood.

19. A method as claimed in claim 17 or claim 18 wherein said lymphocyte cells are T-lymphocyte cells.

20 20. A dormant lymphocyte cell population obtained by the method of any one of claims 17 to 19.

Cells, Culture Methods and their Uses

5 The present invention relates to autologous
transplantation therapy and in particular to the removal
of samples of eukaryotic tissues or cells from a healthy
host organism for subsequent transplantation to that
10 host, after a temporal change to the host, for example
when the need arises, e.g. a therapeutic need. The
advantages are that cells held in suspended animation
(ie. dormant cells) can be manipulated and/or
revitalised at a future date when required eg. for
therapy. Cell samples in a state of suspended animation
15 can also be accumulated by performing several rounds of
harvesting of primary samples from the same source
organism(s) prior to the manipulation and/or
revitalization.

20 The maintenance and replication of eukaryotic cells in
culture has been practised for many years. Studies at
the beginning of this century (Proc. Soc. Exp. Biol.
Med. 4 (1907) 140; J. Exp. Med. 15 (1912) 516) have
demonstrated that it is possible to remove animal or
25 human tissue samples and maintain the cells therefrom in
in vitro culture for various lengths of time depending
upon the culture conditions. Most early culturing
consisted of immersing animal tissue or cells in blood,
or blood components such as serum. Blood or serum was
30 the major component of the medium within which
tissue/cell samples were cultured. However, as our
knowledge of the in vitro requirements of cells has
increased, the use of serum or blood components in cell/
tissue culture medium has decreased to the extent where
35 fully defined media are now available which provide all
the nutrients and supplements necessary to maintain at
least some cell types in culture (see e.g. Freshney's

- 2 -

Tissue Culture of Animal Cells, (Culture of Animal Cells: A Manual of Basic Technique, Wiley Liss, 1994)).

However, the maintenance of eukaryotic cells in culture for sustained periods has always been and remains fraught with difficulty. The major problem is that it is generally not possible to keep eukaryotic cells taken from multicellular organisms in primary culture for more than a few days to weeks. This is because cells in primary culture have a limited lifespan. In some instances, though, their maintenance can be prolonged indefinitely. For example, a single cell, or group of cells, can undergo genetic changes which enable it/them to maintain continuous cell replication in an *in vitro* culture environment. Such genetic changes usually involve mutations which activate cellular proto-oncogenes to become oncogenes, and/or mutations which restrict or negate the activity of tumour suppressor genes, leading to the loss of replication inhibition and to the development of cellular immortality (Trends in Genetics 9(1993)138). Our current understanding implies that tumour cells give rise to cancers not because of the sudden activation of immortalizing oncogenes, but because of mutations in genes which normally regulate the cell's ability to limit its own replication. These genetic events, which occur *in vivo* as well as *in vitro*, have led to the generation from multicellular organisms of eukaryotic cell lines that can be maintained in continuous culture (Culture of Animal Cells: A Manual of Basic Technique, Wiley Liss, 1994).

Although it is possible to maintain cell lines in culture, their ability to undergo continuous replication may make it disadvantageous or undesirable to do so. In order to save on resources, it would be better if it were possible to store cells until they were required for culture. Technologies permitting such storage have

- 3 -

been developed, with much information coming from studies with prokaryotic organisms.

5 Early work with prokaryotic organisms such as bacteria and viruses showed that it was possible to keep them in a state of dormancy for long periods of time without affecting their ability to survive and replicate once revived, or revitalised, from their state of dormancy. It was shown that prokaryotic organisms could be put
10 into a state of dormancy (suspended animation) using a number of methods such as freezing, freeze-drying, drying or by placing them in various organic or inorganic solutions with or without subsequent freezing. The solutions include dimethylsulphoxide (DMSO),
15 ethanol, ether, glycerol, phosphate buffered sodium chloride, and serum, or mixtures thereof, or with any other substance that can prolong shelf-life but is not confined to them.

20 Many, if not all, of the methods for placing or maintaining prokaryotic cells in a state of dormancy have also been applied to eukaryotic cells.

Maintaining cells in a culture environment enables
25 manipulations to be performed on cells *in vitro*, and this advantage has led to the development of cell-based assays in diagnostic technology. Cell culturing, therefore, either prior to inducing dormancy or after cell revitalisation has been shown to have important
30 applications for diagnostic medicine as well as basic science (Bone 22(1998)7; J Bone Min Res 13(1998)432).

In addition to medical diagnosis, cell culture methods have also been applied to medical therapies. For
35 example, in cases where patients are suffering from leukaemia, one approach to alleviate the disease is to eradicate the patient's tumour cells by radiotherapy,

- 4 -

chemotherapy and/or surgery. However, radiotherapy and chemotherapy, which are seemingly the only practical treatments for diseases which are systemic and/or metastatic, may also destroy or substantially deplete the patient's normal, non-tumour haematopoietic cells. Consequently, it is standard practice to replace the patient's depleted normal cells with those from the bone marrow of a donor. The donor is often a close relative whose 'tissue-type' is similar to that of the patient, and the donor tissue is therefore less likely to be rejected by the patient (Adv Immunol 40(1987)379).

In addition to possible rejection of the grafted cells by the host, there is also the potential problem of graft versus host (GVH) disease. The vast majority of lymphocytes in a marrow donor sample are immature and unable to elicit a full-blown immune response without first undergoing a process of maturation. Maturation occurs when lymphocytes are processed via the thymus. If immature lymphocytes from the donor are processed through the new host's thymus they will accept the host as "self". However, it is inevitable that a proportion of the donor T-lymphocytes will have undergone maturation via the donor's thymus prior to transplantation, and, consequently, might regard the recipient as foreign. If so, the mature donor T-lymphocytes may attempt to attack the host's cells leading to GVH disease (Immunol Rev 157(1997)79).

To reduce the possibility of the graft rejecting the host, the donor marrow samples can be trawled with, for example, antibodies which specifically recognise and bind to mature T-cells allowing for their removal or lysis prior to transplantation (Curr Op Oncol 9(1997)131). It can be seen, therefore, that the *in vitro* culture of donor human cells and their manipulation prior to grafting is a recognized

- 5 -

methodology in transplantation therapy.

For the treatment of diseases such as leukaemias and lymphomas it is often more practical to provide donor marrow well before it is required for transplantation to the patient. In these instances, the donor marrow sample is made dormant e.g. by the addition of DMSO to the sample followed by freezing of the sample. The donor sample may be kept in a frozen state for, potentially, many years prior to its use for grafting, with little deterioration. Moreover, the donor cells may be manipulated, eg. the mature T-lymphocytes removed, either before or after freezing. The ability to store the marrow samples for long periods has enabled donor marrow banks to be set up to support treatment programmes for patients with various leukaemias and lymphomas (Bone Marrow Transpl 17(1996)197).

The recognition that it was mature T-lymphocytes in donor marrow that caused GVH disease, and the development of technologies to effectively remove them from donor marrow, has helped make significant advances in bone marrow allografting.

By way of definition, allograft means cells or tissue grafted or transplanted between different members of the same species; a xenograft is a transplant of tissue/cells between members of different species; and an autograft is a tissue/cell graft from self to self.

Prior to the scientific advances which made allografting feasible for the treatment of lymphoma and leukaemia, bone marrow transplantation was restricted to autografting (Stem Cells 13(Suppl 3)(1995)63). As defined above, autografting is where cells/tissue are removed from an individual, and grafted back to the same individual. Autografting remains commonplace, and is

- 6 -

particularly relevant in the treatment of burns where skin is removed from undamaged regions of the body and grafted to help repair/regenerate the damaged skin areas (Burns 24(1998)46). Autografting is also common in
5 orthopaedic surgery where the patient's own bone is taken from eg. the pelvis, rib, or chin and used to augment/repair bone in another region of the body, eg. the face (J Oral Maxillo Surg 54(1996)420).

10 Autografting for the treatment of leukaemias and lymphomas has advantages and disadvantages. The key advantage to the patient is that there is no problem of rejection (either by the patient or by the graft) when
15 cells/tissue from the patient are returned to the patient. The main disadvantage, though, is that the grafted cells/tissue removed for subsequent grafting may contain diseased cells. The value of autografting, therefore, is dependent on the ability to obtain or produce donor tissue which is disease-free.

20 Leukaemias and lymphomas, by definition, are diseases affecting cells of the blood and the lymph, and the medical consensus is that seeding or infiltrating of diseased cells to bone marrow can occur irregularly, may
25 involve specific bone marrow sites, and/or happen late in the onset disease. Hence, the rationale for autografting leukaemia/lymphoma patients is that, once the patient has been treated by radiotherapy and/or chemotherapy to destroy tumour cells, it should be
30 possible to return their own, essentially disease-free, bone marrow.

To further ensure that the autografted sample is essentially free of disease, it can be treated in a
35 number of ways. For example, it can be purged by separating/destroying residual tumour cells in the sample. A common purging method, for instance, is to

- 7 -

apply tumour cell-identifying antibodies to tag the
tumour cells in the sample - the tumour cells can then
be removed using cell-sorting technology such as
fluorescence-activated cell sorting (Curr Op Hematol
4 (1997)423).

The value of autografting for the treatment of
metastatic or systemic disease such as leukaemia and
lymphoma remains questionable, though, since the donor
sample may still contain some element of the disease
which cannot be completely purged with current
technologies. The quality of the autograft will also
depend on the status of the disease in the donor
material eg. the type and aggressive nature of the cells
involved, the ability of diseased cells to seed the
marrow, and the time from onset of the disease when the
donor sample was taken. In essence then, the value of
an autograft in such circumstances is empirical and will
vary significantly between individual patients who
present with various symptoms of proliferative disease.

Advances in therapy continue to be made, and our greater
understanding of disease processes helps us to modify
and refocus our therapeutic approaches to alleviate
disease and suffering. Such understanding has been
greatly advanced by technological improvements in the
field of molecular biology. We are now in a position to
follow the pathogenesis of diseases at a molecular
level, and recognize the importance of an individual's
genetic make-up in predisposing them to certain
diseases. For example, we are aware that some
individuals, because of their genetic composition, are
prone to cancers, e.g. leukaemias and vascular disorders
such as heart disease. They may be also predisposed to
neurodegenerative diseases such as Alzheimer's disease
and Huntington's chorea, as well as to endocrine and
exocrine diseases such as diabetes and hypothyroidism,

- 8 -

and skeletal disorders such as age-related osteopaenia, osteoporosis, arthritis and periodontal disease.

Through genetic testing, therefore, it is now possible to identify those individuals predisposed to debilitating diseases.

Furthermore, our knowledge of the body's immune system, and in particular the way in which it recognises and kills virally-infected and tumour cells, continues to advance. We now know that in order to elicit cell-mediated immunity, an offending cell (e.g. a virally-infected or tumour cell) must co-present an HLA class I restricted tumour or viral epitope with danger signals such as GM-CSF and/or TNF- α , so that the antigen-presenting cells (APC) of the immune system will express co-stimulatory signals such as B7 and IL-12 in conjunction with antigen to the interacting cytotoxic T-lymphocyte (CTL) population. The co-presentation leads to the production of clones of both activated and memory cells (for review see Nature Medicine Vaccine Supplement 4(1998)525). In the absence of these additional signals, HLA-I antigen-restricted T-cells which recognise offending cells are processed for destruction or desensitization (a bodily process presumably put into place to avoid the development of eg. autoimmune disease). The induction of such tolerance is because of either ignorance, anergy or physical deletion (Cold-Spring Harbour Symp Quant Biol 2(1989)807; Nature 342(1989)564; Cell 65(1991)305; Nature Med 4(1998)525). It is now clear that tumour cells do not automatically co-present danger and/or co-stimulatory signals. Hence, the spawning of a tumour may lead to eradication of the very cells that provide cell-mediated immunity against the tumour. A patient presenting with a cancer, leukaemia/lymphoma or sarcoma etc, therefore, may have already removed their innate ability to destroy the tumour, by default. However, if the required T-

- 9 -

lymphocytes, or a sample thereof, were removed from the patient prior to the onset of proliferative disease, the relevant T-cell population could now be returned to the patient, after the necessary co-stimulation of the T-cells, so as to alleviate disease.

The present invention is based on our recognition of this possibility, namely the concept of removing cells or tissues from a healthy host organism for subsequent transplantation to that same host organism in a subsequent autologous (autogeneic) transplantation procedure, when the need or desire to do so arises.

In one aspect, the present invention thus provides use of a host cell population obtained from a non-diseased host organism for the preparation of a cell composition for use in subsequent autologous transplantation therapy of said host organism.

Alternatively expressed, and in another aspect, the invention provides a method of autologous transplantation therapy, said method comprising transplanting a host organism with a cell composition prepared from a host cell population obtained from said host organism when non-diseased.

More particularly, this aspect of the invention provides a method of autologous transplantation therapy, said method comprising obtaining a population of host cells from a non-diseased host organism; and preparing a cell composition from said host cell population for subsequent transplantation to said host organism.

A further aspect of the invention provides a cell composition comprising a host cell population obtained from a non-diseased host organism for use in subsequent autologous transplantation therapy of said host

- 10 -

organism.

A still further aspect of the invention provides use of a host cell population obtained from a non-diseased host organism for subsequent autologous transplantation therapy of said host organism.

The host organism may be any eukaryotic organism, but preferably will be an animal, more preferably a mammal, and most preferably a human. Other representative host organisms include rats, mice, pigs, dogs, cats, sheep, horses and cattle.

The term "non-diseased" is used herein to describe a state in which the organism is healthy, ie. not suffering from any disease or disorder, or is not manifesting any symptoms of said disease or disorder ie. is asymptomatic or is in a pre-clinical condition. In particular, the host organism is not suffering from, or demonstrating symptoms of, the disease or disorder, which it is subsequently intended to treat by the transplantation procedure.

Furthermore, in certain embodiments of the invention, the host organism is preferably not predisposed to, or at risk from, any particular disease or disorder e.g. preferably not exhibiting any symptoms or manifestations predictive of a subsequent disease or disorder. Likewise, the host organism is preferably not suffering from any injuries or damage which may give rise to an anticipated or expected condition. A major idea or concept behind the present invention is to harvest or collect the host cells from the host organism at a stage when there is no direct prediction, suggestion, or suspicion that a particular disorder or disease may develop, for use against a future possible or unpredicted event, or an event which may occur simply by

- 11 -

chance, rather than an anticipated or suspected or predicted illness or condition.

Also included, is the removal of cells from a "non-diseased" region or area of the body of the host organism, even though other areas or regions of the body or cells or tissues of the body may be affected by a disease or disorder. What is required is that the cells removed are themselves healthy ie. "non-diseased" within the definition given above.

In preferred embodiments of the invention the cells are obtained from the host organism before any disease or disorder develops or manifests itself, and more preferably when the host organism is in general good health, and preferably not immunocompromised in any way.

Advantageously, therefore, the host cells are obtained from host organisms when they are young, preferably in adolescence or early adulthood. In the case of humans, cell sampling at the ages of about 12 to 30, preferably 15 to 25 is preferred. Especially preferably, sampling is from the age of 16 or 17 upwards, for example in the age range 16 to 30, 17 to 30, or 18 to 30, or perhaps 18 to 35 or 40. It is thus preferred that the cells be obtained when the host organism is mature, or reaching maturity, but before the processes of ageing or senescence have significantly set in. In particular, it is preferred and advantageous that the immune system of the host organism is mature or fully developed.

However, the obtention of cells outside these ranges is encompassed, and cells may be obtained at any post-natal life stage e.g. from juvenile host organisms e.g. in mid-to late childhood, or even infants, or from older individuals, as long as they remain "non-diseased". Foetal host organisms are thus excluded from the present invention and sampling of foetal cells is not

- 12 -

encompassed.

In contrast to sampling umbilical blood for example, the advantages of the present invention are that taking
5 cells from post-natal or older hosts allows multiple samples to be collected, thereby increasing the opportunity of storing sufficient number of cells. In addition sampling from juvenile or older hosts overcomes the ethical requirements such as providing informed
10 consent.

Sampling from adolescent or adult host organisms is preferred since the sampled cells, from blood in particular, will contain a greater proportion of
15 valuable mature T-cells capable of recognising aberrant cell populations, such as cancer cells or virally-infected cells. Thus, when blood samples are used, it is advantageous that they are taken from an individual with a mature immune system (ie. not foetal or neo-
20 natal).

The term "autologous" is used herein to mean that the transplantation is to the same organism (ie. the same individual) from which the host cells were removed.
25 Thus, autogeneic transplantation [self-to-self] or autografting is intended.

"Transplantation" refers to any procedure involving the introduction of cells to an organism. Thus, any form of
30 transplantation or grafting known in the art is encompassed.

"Transplantation therapy" refers to any procedure involving transplantation of cells. Both therapeutic
35 (e.g. curative or palliative, or symptom-relieving) and prophylactic (ie. preventative or protective) therapies are covered. Thus, the term "transplantation therapy"

- 13 -

encompasses the transplantation of cells to a host organism in need thereof, or in anticipated, expected or suspected need thereof, for any reason. Advantageously, the transplantation therapy is to treat or alleviate a disease or disorder which develops, or is threatened, subsequently, e.g. cancer or infection, or a degenerative condition (e.g. neuro-degenerative).

The host cells may be, or may comprise, any cells of the host organism, including both individual cells and cells comprised or contained in any tissues of the body, including both body fluids and solid tissues. The term "host organism" as used herein means the post-natal body, and does not include "waste" or "disposable" tissues which are not part of the body *per se*. Thus, the umbilical cord and placenta are not included. However, any part of the actual body of the host organism may be used as the source of the host cells. Representative cells thus include haemopoietic cells, e.g. blood cells, spleen cells, thymus cells or bone marrow cells; neural tissue cells (i.e. cells of the nervous system); liver cells; pancreatic cells; skin cells; hair cells; gut cells; marrow stromal cells which derive myoblasts, chondroblasts, adipocytes, osteoblasts, fibroblasts and their progenitors, or cells of any body organ or tissue. Preferred sites of removal of cells from the body include bone marrow, bone marrow stroma, neural tissues, internal organ tissues or dermal tissues. All cell types are encompassed, as are different stages of cell differentiation, including both undifferentiated, and partly or fully differentiated cells, e.g. stem, progenitor or precursor cells or fully differentiated cells.

Stem or progenitor cells are particularly included according to the invention, including both pluripotential stem cells and stem or progenitor cells

- 14 -

already committed to a particular path or paths of differentiation. Particular mention may be made of haemopoietic stem cells and neural stem cells, marrow stromal stem cells, gut stem cells, dermal stem cells and other epithelial stem cells.

A preferred cell type according to the invention is the lymphocyte, especially a T-lymphocyte (a T-cell) which may be obtained from any convenient source in the body, advantageously blood, bone marrow, thymus, lymph or spleen. Mature T-lymphocytes are particularly preferred.

Other preferred cell types and sources include osteoblasts, chondroblasts, chondrocytes, adipocytes and fibroblasts, which may be marrow stroma-derived.

Still other preferred cell types and sources include neuronal cell types (such as striatal, cortical, motorneuronal, dopaminergic, noradrenergic, serotonergic, cholinergic cells) from the brain and spinal cord, or glial cell types (such as oligodendrocytes, Schwann cells, astrocytes and microglia) from the central and peripheral nervous system.

The disease or disorder which may be treated by the transplantation therapy may be any disease or disorder known to man. Thus any disease condition, illness, disorder or abnormality of the body is included.

Mention may be made, for example, of infections e.g. diseases arising from pathogenic activity e.g. bacterial, fungal or viral infections, or infections by any other organism e.g. a protozoa or other parasite; any malignant or pre-malignant condition; proliferative or hyper-proliferative conditions; or any disease or diseases arising or deriving from or associated with a functional or other disturbance or abnormality, in the

- 15 -

cells or tissues of the body, e.g. aberrant gene expression or cell or tissue damage (whether induced or caused by internal or external causes e.g. ageing, injury, trauma or infection etc.), or idiopathic diseases (e.g. Parkinson's disease).

Advantageously, the present invention has particular utility in the therapy of chronic conditions (ie. chronic diseases or disorders).

Representative diseases or disorders thus include any cancer (whether of solid tissues of the body (e.g. prostate or mammary tumours), or of haemopoietic tissues or other individual cells, in particular leukaemias or lymphomas), vascular disorders, neural disorders including in particular neuro-degenerative conditions, endocrine and exocrine diseases and skeletal disorders, as discussed above, or any condition associated with ageing or senescence. Particular mention may be made of osteoporosis and osteoarthritis.

Therapy of cancer represents a preferred embodiment of the invention, and includes cancers of any cells or tissues of the body. The invention is not limited to any one type of cancer (e.g. leukaemia, lymphoma, carcinoma or sarcoma), nor is it restricted to specific oncogenes or tumour-suppressor gene epitopes such as ras, myc, myb, fos, fas, retinoblastoma, p53 etc. or other tumour cell marker epitopes that are presented in an HLA class I antigen restricted fashion. All cancers such as breast, stomach, colon, rectal, lung, liver, uterine, testicular, ovarian, prostate and brain tumours such as gliomas, astrocytomas and neuroblastomas, sarcomas such as rhabdomyosarcomas and fibrosarcomas are included for the therapy by the present invention.

A further preferred embodiment of the invention is the

- 16 -

therapy of infections, particularly viral infections, including HIV and other infections which may have a latent phase.

- 5 The host cell population which is obtained, or removed, from the host organism may comprise one or more cells, or may comprise a tissue sample which is removed from the body.
- 10 The host cell population which is used according to the invention for a subsequent transplantation procedure to the host organism, may be used at any convenient or desired time after removal from the host organism. In order words a tissue or cell sample removed from an
- 15 individual may be used at a future date when required for use in therapy. Advantageously, however, the invention permits the subsequent transplantation to be at a prolonged time interval after the cell removal, e.g. from 3 months to many years (e.g. up to 80 years or
- 20 more). Thus, the invention allows healthy, non-diseased cells to be removed from an individual when in good health, or good immunological status and used, many years later, for therapy of that individual, when a problem develops. Preferred or representative time
- 25 intervals for subsequent transplantation thus include 6 months to 70 years, 1 to 50 years, and 1 to 30 years or 5 to 30 years. Conventional cryopreservation conditions and procedures allow for such periods (Scand. J. Haematol. 10 (1977) 470; Int. J. Soc. Exp. Haematol. 7
- 30 (1979) 113).

The host cell population may be obtained or removed from the host cell organism in any convenient way. This may depend on the cells and the location in the body from

35 which they are obtained.

Recent advances have been made in the way cells may be

- 17 -

obtained for subsequent grafting. The advent of molecular biology has helped us to understand more clearly the basic biology of cell growth and function in health and disease. For example, investigations into the agents which regulate haematopoiesis have led to the isolation of a series of factors that influence the proliferation and differentiation of lymphocytes - these include the cytokines such as the interleukin series IL-1-IL-18 and the leukotrienes; and growth factors such as the TNF's, the TGF's, FGF's, EGF's, GM-CSF, G-CSF and others. A number of these factors are now available commercially for clinical use, and some have been shown to increase substantially the number of lymphocytic cells and, in particular, immature T-lymphocytes in the peripheral blood. Their administration to the host organism means that, after a few days to allow an effect, it is possible to filter large quantities of the cells of interest, eg. immature T-lymphocytes, directly from host's blood without the need to sample the marrow (Stem Cells 15(1997)9). The technology for extracting lymphocytes from blood, by removing blood from the patient, passing it through a cell separator and then returning it to the patient, all virtually simultaneously, has been available for many years (Practical Immunology, 3rd Edition, Blackwell Scientific Publications, 1989).

Biopsy procedures may also be used to facilitate removal of other cell types, or cells from other locations. For example, Example 5 describes how brain cells may be obtained. Gut samples may be obtained, e.g. from stomach, intestines or rectum, by endoscopic biopsy. Fine needle aspiration may be used for thyroid or other tissues.

Selective cell isolation procedures for desired cell types may also be possible, see e.g. JP-A-10033165

- 18 -

(Abstract) for selective isolation of haemopoietic undifferentiated cells.

5 The removed host cell population may be stored, cultured, handled, manipulated or treated in any known or desired manner for subsequent transplantation (i.e. to prepare the cell composition for transplantation). Cell handling, culture and storage procedures are well known in the art and widely described in the literature, 10 and any of the standard procedures may be used. Cells may be stored in any convenient or desired medium, e.g. as known in the art. (See e.g. Freshney's (supra) for cell culture requirements and WO 98/33891 for lymphocyte preparation).

15 Conveniently, the host cell population may be put into a state of dormancy. The term "dormancy" as used herein includes any state of suspended animation or stasis, and procedures for achieving this are well known in the art, 20 as described above. Any of the known procedures may be used (see e.g. Freshneys, supra). Thus, the cells may be held or maintained in a quiescent, inactive or non-proliferating state.

25 According to a preferred procedure, the cells are frozen preferably to a temperature below -160°C .

A particularly preferred means of achieving dormancy is to freeze the cells to the boiling point of helium (He) 30 ie. to about -269°C or below.

Thus, in a further aspect, the present invention provides a method of making and/or maintaining cells dormant, said method comprising freezing said cells to a 35 temperature at or below -269°C .

Dormant cell populations obtained by such a method also

- 19 -

form part of the invention.

As described in Freshneys (supra), the cells may be suspended in a suitable medium (e.g. containing 5-10% DMSO) and cooled at a controlled rate e.g. 1°C per minute to -70°C, then into liquid/gas N₂. Such conventional procedures may be adapted to cool the cells into He/N₂ mixtures or He.

Results have been obtained which show that by using the (ie. the lower temperature) improvements in the long-term viability of the cells may be obtained. When multiplied over 10-20 years for example, this enhancement in viability may be important in the successful storage of the cells (see Example 6 below).

Alternative methods of achieving and/or maintaining cell dormancy include cooling to 4°C.

The cells may be cultured if desired, for example as part of a treatment or modification process (see later) or they may be expanded ie. they may be cultured to increase cell numbers. For example, the cells may be passaged, according to methods well known in the art. The culturing may be before or after the period of dormancy, or both.

Prior to transplantation, the cells may also or alternatively be modified or manipulated in some way, e.g. genetically or functionally and/or by inducing or modulating their differentiation. Again, as described above, this is known in the art and any of the known or standard procedures may be used. (see e.g. WO98/06823, WO98/32840, WO98/18486). Such modification or manipulation may be carried out before or after dormancy, or both. The modification/manipulations are not restricted temporally, in that the sequence and/or

- 20 -

number of manipulations is flexible.

Thus, genetic interventions may include regulating or modifying the expression of one or more genes, e.g. increasing or decreasing gene expression, inactivating or knocking out one or more genes, gene replacement, expression of one or more heterologous genes etc. The cells may also be used as a source of nuclei for nuclear transfer into stem cells.

The cells may be exposed to or contacted with factors, e.g. cytokines, growth factors etc. which may modify their growth and/or activity etc, or their state of differentiation etc. The cells may also be treated to separate or selectively isolate or enrich desired cell types or to purge unwanted cells.

Thus, for example a T-cell modificatory method is discussed above, whereby T-cells are co-stimulated prior to transplantation.

Alternatively, haematopoietic cells may be co-presented with HLA class I restricted tumour antigen and B7 and/or IL12, so as to produce both activated and memory T-cells. The sample may then returned to the host organism before the onset of disease, as a prophylactic therapy. Alternatively, the co-presenting antigen-presenting cells (APCs) may be returned to the host along with the activated and/or memory T cells.

Alternatively, the cells may be exposed to the host's tumour in vitro with appropriate danger signals and co-presentation of co-stimulatory molecules, before being returned to the host. As with our WO96/15238 directed to T-lymphocyte therapy, the host's CTLs may be genetically modified to recognize the tumour prior to replacement. The alternatives in this paragraph provide for functional interactions between haematopoietic cells

- 21 -

either prior to, or after a period of dormancy or combination.

Following dormancy, the cells are revitalised prior to use in transplantation. Again, this may be achieved in any convenient manner known in the art, and any method of revitalising or reviving the cells may be used.

Conveniently, this may, for example, be achieved by thawing and/or diluting the cells, e.g. as described in the Examples. Techniques for revitalisation are well known in the art (see e.g. Freshney's supra). Cells may be thawed by gentle agitation of the container holding the cells in water at 37°C, followed by dilution of DMSO to 1% or below, e.g. with medium, or patient serum etc. Cells may be implanted immediately or after recovery in culture. Revitalisation is designed to re-establish the usefulness of the cells e.g. in prophylaxis or curative therapy.

The invention relates to the recognition that a tissue sample from a non-diseased individual may be put into a state of dormancy. The tissue may then be revitalized and returned to the same individual when required at a later date. Grafting the revitalized tissue 1, 2, 3, 4, 5, 6 or more months or 1, 2, 3, 4, 5, 6 or more years after its removal from the patient is intended to alleviate or protect against disease, to slow the progression of disease, or to augment and/or support the functioning of the remaining normal, or damaged, tissue in the patient. The invention is clearly distinct from the freezing of bone marrow cells from patients with eg. leukaemia, and from the freezing of gametes, eg. sperm, prior to treatment of patients with eg. childhood leukaemia, because the patients already have disease. It is also distinguished from patients who provide blood for chilled storage for possible later use, eg. at a

- 22 -

subsequent operation, for the same reason. In addition, the duration of storage for the possible return of such a blood sample is commonly only up to one month. Similarly, individuals with no diagnosed abnormality may choose to provide blood for chilled storage for prospective use by themselves prior to travelling abroad. Such use might include for the treatment of hypovolaemia after acute blood loss, such might occur after a road traffic accident or other trauma, but this again is for a short period of storage of about one month only, and not intended for use in future disease e.g. chronic disease.

A number of particularly advantageous applications of the invention can be identified. Firstly, for individuals who are predisposed to blood disorders such as leukaemia or lymphoma but have not succumbed to, or are asymptomatic for, the disease prior to sampling, the invention provides a prospective therapeutic method. It would be beneficial for such presently healthy individuals to provide a tissue sample or multiple tissue samples (eg. bone marrow or blood). The sample/s could be kept in a state of dormancy until their use at a future date to replace/augment aberrant or lost tissues/cells and alleviate the disease they were likely to contract after the sample was taken. The invention may also have applicability for individuals whose environments pre-dispose them to e.g. leukaemia, for example power station workers. The invention is against all conventional teachings, then, which recommend retrospective allografts or autografts to provide a curative intervention in diseases such as leukaemia and lymphoma or solid tumours. Other types of pre-disposition are also included within the scope of this aspect of the invention, as indeed are other factors e.g. a family history which might suggest a risk of a suspected condition.

- 23 -

A further advantageous utility of the invention is in the treatment of HIV infection or disease. Thus, CD4⁺ cells can be collected from an individual when healthy or non-infected, and stored for subsequent
5 transplantation into said individual when HIV infection manifests itself or when AIDS develops, or CD4⁺ cell count falls etc. Such a procedure may be attractive to an individual with a life-style likely to place them at risk from contracting HIV infection.

10 In addition, it is well recognized that the ageing process makes individuals more susceptible to disease. The basis for the susceptibility appears to be in the loss of immune function resulting from a significant
15 decrease in T and B cell numbers/activity during ageing (Mech Ageing & Dev 91(1996)219; Science 273(1996)70; Mech Ageing & Dev 96(1997)1).

20 Furthermore, the invention can be seen as being particularly advantageous in the light of recent discoveries related to the down-regulation of cytotoxic T-lymphocyte activity in response to HLA class I antigen-restricted tumour-epitope presentation.

25 Disease susceptibility is particularly pertinent when elderly patients are subjected to eg. surgery in a hospital environment, where they are prone to opportunistic infections with serious or even fatal consequences. Marrow and/or blood samples taken much
30 earlier in life from the patient, such as during adolescence or early adulthood when their immune system is mature but uncompromised, and maintained subsequently in a state of dormancy, could be revitalized and reinfused to the patient to boost their immune system.
35 Such an approach would provide for a method of augmenting the patient's immune system after surgery in order to lessen the likelihood of post-operative

- 24 -

complications caused by opportunistic infections. The invention, therefore, could be used as a prophylactic therapy, eg. for elderly patients when they are more susceptible to disease.

5

10

15

Another area in which the invention can be seen to have particular advantages is where individuals may be predisposed to endocrine disorders in later life such as diabetes, hypothyroidism or hypoparathyroidism, or to the loss or disease of skeletal material leading to age-related osteopaenia, osteoporosis, osteoarthritis, rheumatoid arthritis, and periodontal disease. Tissue/cell samples could be taken from these individuals, stored in a state of dormancy, and then reinfused back, optionally after *in vitro* expansion, into the individual when their endocrine/skeletal status indicated a requirement.

20

25

30

35

The recent discovery that neural stem cells exist in even the adult brain means that sampling from eg. the ventricular surface of the brain will permit expansion *in vitro* of such stem cells to provide large neural cell populations. These may then be used as a source of material for grafting back to the same individual who may in the meantime have succumbed to, or become symptomatic for a neural disease or disorder eg. Parkinson's disease, Huntington's chorea, multiple sclerosis, stroke injury, Alzheimer's disease, amyotrophic lateral sclerosis, Pick's disease, Creutzfeld-Jacob disease or other neurodegenerative disorders. Furthermore, the invention has particular advantages in the treatment of neurodegenerative illness with a genetic component. This is because the donor cells can be modified genetically, either before or after dormancy to, for example, override, negate, alleviate or reverse the effects, future or current, of the abnormal inherited component of the disease. In

- 25 -

Huntington's chorea, for example, the IT15 gene coding for huntingtin contains an abnormally large number of CAG repeats (Cell 72 (1993) 971). This dominant gene may be inactivated or knocked out *in vitro*, and replaced
5 by the normal version (J. Neuro Sci: 18 (1998) 6207; Bioessays 20 (1998) 200). The present invention has clear advantages, therefore, in the treatment of neurodegenerative disease, by providing graftable (PNAS
10 89 (1992) 4187), and in this case autograftable material, both with and without prior modification of the cell's functionality, differentiation or genotype. Analogous principles would apply to the treatment of other diseases or disorders.

15 The invention would also have advantages where cell/tissue samples need to be transported to specialist laboratories to undergo manipulations (eg. genetic modifications e.g. nuclear transplantation into stem
20 cells) prior to their return to the patient. Often, it may not be possible to treat/modify the cells, either genetically or functionally, or phenotypically at the place where the patient is sampled. Even if it is possible, the process may not be immediately
25 initiatable. Placing the sample in a state of dormancy may be considerably advantageous to the procedure, as the cell manipulations that need to be made can be performed at a time suitable to the management of the
30 process eg. either before making the cells dormant or after they are resuscitated, but before they are returned to the patient.

The invention would be seen also as advantageous when a multiplicity of samples from a single donor are needed. The invention could be used to build a stock by multiple
35 sample additions (i.e. 2 or more) to the first sample, all of them being placed in a state of dormancy prior to revitalizing part of, or the complete collection for

- 26 -

use, for example, in therapy. The donor tissue for autografting may be from animals including transgenic animals. Such animals would include, but not be limited to, rats, mice, pigs, dogs, cats, sheep horses and cattle.

The invention may also include the incorporation of a negative selection marker into all cells/tissues destined to be returned to the patient as described, for example, in WO96/14401 (Transgenic organisms and their uses), and WO96/14400 (Genetically modified neural cells) the contents of which are incorporated herein by reference.

The invention will now be described in more detail in the following non-limiting Examples, with reference to the drawings in which:

Figure 1 is a histogram showing the effect of reinfusion of cryopreserved autologous white cells on survival of X-irradiated rats (numbers of surviving rats vs Time (weeks) after irradiation). Rats were maintained under SPF (specific pathogen-free) conditions. Five ml of whole blood was removed by cardiac puncture from all rats two weeks prior to irradiation. White cells were prepared as described earlier from five of the blood samples and then cryopreserved using standard procedures (see Example 1). At time zero, all rats were given 8 Gy of X-irradiation. Two weeks following the irradiation five rats (solid bars) were infused with autologous grafts of thawed white cells and control animals (striped bars) received autologous grafts of thawed white cells and control animals (striped bars) received autologous plasma vehicle alone. Two days later, all rats were removed from SPF conditions and returned to the main animal housing facility. Death of animals through opportunistic infection was monitored. The

- 27 -

experiment demonstrates that reinfusion of white cells into irradiated rats protects such immune-depleted animals from death by infection.

5 Figure 2 is a histogram showing maintenance in grafted rats of autologous, engineered T-lymphocytes up to six months after grafting, the full period of study (numbers of rats vs time (months)). Five ml of peripheral blood was removed from each of ten rats by cardiac puncture.
10 The white cells were enriched from the samples as described in Example 1 and then genetically engineered to contain the hygromycin resistance gene (W096/15238). The cells were cryopreserved as described earlier. Six months after cryopreservation, the cells were thawed and
15 autologous reinfusion performed. The presence of DNA encoding the hygromycin resistance gene was analyzed by PCR at three-monthly intervals. The experiment shows the continuing presence of hygromycin-resistance gene-containing cells.

20 Figure 3 is a histogram showing the results of an identical study to that described in Figure 2, except that the genetic engineering step was performed after, rather than before the cryopreservation stage. The
25 presence of DNA encoding the hygromycin resistance gene was analyzed by PCR at three-monthly intervals. Similar results to those found with a pre-preservation engineering step were obtained, indicating the prolonged survival of the cells after return to the host.

30 Example 1

Survival of infection through prospective autologous grafting of frozen stored donor cells

35 (i) Samples taken

Both male and female Wistar rats were used in this

- 28 -

study. A number of standard procedures were employed to extract either marrow samples or peripheral blood samples (see below). Reference to these procedures can be found in human or animal surgical texts such as that
5 by Waynforth and Flecknell (Experimental and Surgical Technique in the Rat, 2nd Edition, Academic Press, 1992).

(ii) Methods of sampling

10 In brief, animals were anaesthetised with chloroform and anaesthesia was maintained with halothane. Bone marrow cells and/or blood cells were sampled using standard procedures. All sampling was performed under anaesthesia. Blood was sampled by cardiac puncture, or
15 by exposure of the jugular vein followed by blood extraction therefrom. Marrow was extracted from the femur after a hind leg amputation; and from the tibia and fibula of the amputated hind leg. (Practical Immunology, 3rd Edition, Blackwell Scientific
20 Publications, 1989). For marrow sampling the rat femur and/or tibia was exposed and bone marrow cells removed using disposable bone aspirating needle(s) or an Islam bone marrow harvesting needle, or equivalent thereof, for rats. Several areas of the bone were sampled so as
25 to provide an adequate harvest of marrow cells for future needs. Alternatively, a rib biopsy was taken which was particularly advantageous for the sampling of bone cells of the CFU-F (colony forming units-fibroblast) type. For humans, the iliac crest is
30 usually sampled.

(iii) Marrow cell preparation

Once obtained, the marrow cells were suspended in culture medium and separated from fatty materials
35 essentially as described previously for human cell sampling (Bone 22(1998)7). The resulting cell suspension was transferred to a universal container and

- 29 -

allowed to stand undisturbed for 10 minutes (min), after which time fat deposits that had floated to the top were removed. The marrow-derived cells were transferred to a centrifuge tube and spun at 100 x gravity (g) for 5 min to harvest the cells. The medium and fat deposits were again removed and the cell pellet resuspended in 5 ml of fresh culture medium. The resuspended cells were loaded onto a 70% Percoll gradient which was centrifuged at 460 g for 15 min. Following centrifugation, the top 25% of the gradient volume, which contained the required marrow cells, was removed. To this suspension an equal volume of fresh medium was added and the suspension centrifuged at 100 g for 10 min. The resulting cell pellet was resuspended in fresh medium and a single cell solution obtained by passing the cells through a 19-gauge needle several times. The number of viable cells was then determined by trypan blue (1% w/v) exclusion.

Alternatively, no separation of the fat cells from the sampled marrow cells was carried out, and the entire sample was prepared for dormancy. Both haematopoietically-derived and mesenchymally-derived tissues could be obtained by marrow sampling such that, in addition to cells of the immune system, cells capable of giving rise to osteoblasts, chondroblasts, myoblasts, fibroblasts and/or adipocytes could be also obtained. The mesenchymal cells can be separated, for example, by taking advantage of their adherent properties. Placing the sampled cells on standard tissue culture plasticware, for varying lengths of time, leads to adherence of the mesenchymal cell population to the plastic, leaving the haematopoietic cells in suspension. The different cell types can be then physically separated by pouring off the supernatant.

All of the above procedures are well known to the man skilled in the art.

- 30 -

(iv) Peripheral blood sampling

Adequate samples of mononuclear cells (white cells) were obtained, alternatively, by peripheral blood sampling. It is well recognised that haematopoietic stem cells, progenitors of T-lymphocytes and mature T-lymphocytes reside in peripheral blood which makes peripheral blood mononuclear cells suitable for transplantation.

Peripheral blood was also sampled from rats given an intraperitoneal injection/s of either granulocyte colony stimulating factor (G-CSF) or granulocyte macrophage colony stimulating factor (GM-CSF) or haemopoietin for periods up to 96 hours prior to sampling. The peripheral blood mononuclear cells were sampled 1 to 4 days after G-CSF/GM-CSF administration. G-CSF and GM-CSF have been shown to increase the peripheral blood mononuclear cell population which comprises haematopoietic T-lymphocytes and their progenitors and stem cells, as well as other blood cells. This approach, therefore, helps to increase, in vivo, the abundance of cells required for subsequent transplantation prior to their removal from the body. The use of agents such as G-CSF, GM-CSF, haemopoietin or combinations thereof 3-4 days prior to sampling of blood by apheresis is a method currently used to obtain peripheral blood stem cells for human therapy and may be used in the invention (Stem Cells 15(1997)9).

(v) Isolation and storage of sampled cells

Peripheral blood from either non-treated or GM-CSF/G-CSF-treated rats was taken, and white cells prepared directly using standard procedures. In short, blood samples were placed in heparinised tubes and high purity lymphocyte preparations obtained by differential centrifugation on a density gradient. After centrifugation, the white cell - containing buffy coat (white cell band), which was clearly visible, was

- 31 -

removed to a fresh cryopreservation container (Practical Immunology, 3rd Edition, Blackwell Scientific Publications, 1989).

5 Alternatively, the marrow cell samples (either non-separated samples, or samples separated into different cell types - e.g. fat/non-fat, mesenchymal/haematopoietic cells) collected were placed in fresh cryopreservation containers.

10

To the blood or marrow samples autologous plasma containing 20% v/v DMSO (or variations of DMSO volume from 5-50%) was added to a final volume that brought the DMSO concentration to approximately 8.25 % (or
15 variations of DMSO volume from 8-50%). The samples were then refrigerated and slowly frozen so as to lose approximately one degree Celsius every 1-2 min until they reached approximately minus 50°C. They were then transferred to gas/liquid-phase nitrogen/helium, or gas
20 and/or liquid nitrogen followed by gas and/or liquid helium for long term storage at approximately minus 196°/269°C until required.

20

25

Rats sampled were given several weeks to recover prior to undergoing further treatment(s).

(vi) Replenishment of the immune system

30

One group of 10 sampled rats received an ablative dose (8 Gy) of whole body irradiation so as to destroy radiation-sensitive cell populations. The radiation dose given has been shown to compromise the immune system which is highly radiation-sensitive, such that animals die readily from infection soon after treatment (Practical Immunology, 3rd Edition, Blackwell Scientific
35 Publications, 1989). Removal of the thymus may have a similar effect.

- 32 -

5 Marrow cells or white cells were thawed from frozen, with gentle agitation of the cryovial in a beaker of 37°C water. Medium was then added to dilute the DMSO eg. 10-fold, and the cells gently pelleted by centrifugation at 400g. The cells were resuspended in a small volume of autologous plasma before being returned to the animal by infusion.

10 Of the 10 irradiated animals, 5 were given autologous grafts two weeks after irradiation, and all rats returned to the animal unit's main housing facility. Within three months the 5 non-autografted rats had died from infection, but the 5 autografted rats all survived the following six months of the study (see Figure 1).

15 Example 2

20 Autologous grafting of genetically engineered stored frozen donor lymphocytes

25 Both male and female Wistar rats were used in the study and marrow cells and/or peripheral blood mononuclear cell samples were obtained as described in Example 1. The mononuclear cells were genetically engineered to express the a and b chains of the T-cell receptor which, when combined, recognised the Mage 1 tumour antigen. The genetic construction also provided hygromycin resistance to the engineered cells and is described further in WO96/15238 - Targeted T-lymphocytes, incorporated herein.

35 Samples of the engineered cells were then cryopreserved for periods up to six months before being revitalised/revived as described in Example 1 and used as autologous grafts. Rats with autologous grafts were sacrificed at various times after grafting, and their blood ex-sanguinated by heart puncture. Genomic DNA

- 33 -

encoding the hygromycin resistance gene, present in the engineered cells only, was detected by the polymerase chain reaction (PCR) as described previously (PCR A Practical Approach, IRL Press, 1991). In brief, peripheral blood mononuclear cells were isolated by differential centrifugation on a density gradient. The buffy coat was separated and genomic DNA prepared by phenol/ chloroform extraction followed by ethanol precipitation and resuspension in sterile water (Sambrook et al., Molecular Cloning. A Laboratory Manual, Vols. 1-3, Cold Spring Harbour Laboratory Press, 1989). The genomic DNA was PCR amplified in the presence of oligonucleotide primers designed to recognise a 272 base pair sequence of the hygromycin resistance gene (see McPherson et al., PCR. A Practical Approach, IRL Press, 1993 for PCR conditions). Hygromycin primers detecting hygromycin gene sequence of size 1.023 kb were as follows:

GAATTCAGCGAGAGCCTGAC (left primer 5'-3')

GATGTTGGCGACCTCGTATT (right primer 5'-3')

A sample of the PCR product was electrophoresed through a 4% agarose gel and the 272 base pair fragment of the hygromycin resistance gene identified by UV transillumination after staining the gel with ethidium bromide. The ability to identify the hygromycin gene in the rat blood samples over time is provided in Figure 2.

Example 3

Genetic engineering and autologous grafting of stored frozen donor lymphocytes

Example 3 was performed as for Example 2, except that the cells for autologous grafting were cryopreserved prior to genetic engineering. Samples were thawed as described in Example 1 prior to autografting.

- 34 -

Results of the maintenance of gene expression in the autograft over time is given in Figure 3.

- 35 -

Example 4Syngeneic and autologous grafting of marrow stromal cells in young and aged rats

5 An inbred strain of Sprague Dawley rats was used for these studies. Suspensions of bone marrow cells (2×10^6 cells per ml) were prepared from rib (also femur) biopsies taken from young rats (8 weeks of age) and aged
10 rats (60 weeks of age). Cell samples were centrifuged at 400 X gravity and the resulting cell pellet(s) resuspended in 10% DMSO in autologous plasma followed by cryopreservation in liquid nitrogen and/or followed by liquid helium.

15 Cell samples were revitalised from 3 months to 2 years after cryopreservation and suspended in culture medium at 2×10^6 cells/ml. To each sample suspension a single porous hydroxyapatite disc was added and left for 24
20 hours to allow cells to adhere to it - producing a cell/HA composite. The composites were then implanted subcutaneously as either autogenous or syngeneic grafts. The grafts were removed after 8 weeks and subjected to histological analysis, and osteocalcin and alkaline
25 phosphatase measurements.

The experimental groups were as follows

30 (1) Marrow cells sampled from young rats aged 8 weeks were incubated with porous hydroxyapatite (HA) for 24 hours to form a marrow cell/HA composite. The composites were then either (a) autogenously grafted or (b) syngeneically grafted to rats of the same age or (c) rats of 60 weeks of age, or (d) rats of 104 weeks of
35 age.

(2) Marrow cells sampled from old rats aged 60 weeks

- 36 -

were incubated with porous hydroxyapatite for 24 hours to form a marrow cell/HA composite. The composites were then either (a) autogenously grafted or (b) syngeneically grafted to rats of 8 weeks of age or (c) syngeneically grafted to rats of 60 weeks of age, or (d) syngeneically grafted to rats of 104 weeks of age.

(3) Marrow cells sampled from young rats aged 8 weeks were cryopreserved as described. After 96 weeks cryopreservation, the cells were revitalised and incubated with porous hydroxyapatite for 24 hours to form a marrow cell/HA composite. The composites were then either (a) autogenously grafted (the sampled rats being 104 weeks of age) or (b) syngeneically grafted to rats of 104 weeks of age or (c) syngeneically grafted to rats of 8 weeks of age.

(4) Marrow cells sampled from old rats aged 60 weeks were cryopreserved as described. After 44 weeks cryopreservation, the cells were revitalised and incubated with porous hydroxyapatite for 24 hours to form a marrow cell/HA composite. The composites were then either (a) autogenously grafted (the sampled rats being 104 weeks of age) or (b) syngeneically grafted to rats of 104 weeks of age or (c) syngeneically grafted to rats of 8 weeks of age.

Results

Qualitative histological analysis demonstrated a clear difference between the ability of young and old marrow cells to induce new bone formation in either autogenous or syngeneic grafts. 40% of old marrow cell/HA composites showed no bone formation when grafted to either young or old rats, whereas bone was formed in all composites comprising young marrow cells. The result was identical for composites where the marrow cells had

- 37 -

been cryopreserved and revitalised prior to grafting.

Differences in osteocalcin expression and alkaline phosphatase activity between composites formed from young and old marrow cells was highly significant. On average, osteocalcin expression was 8-10 fold higher in composites containing young cells when compared to composites containing old cells. The 8-10 ratio of osteocalcin expressed between composites comprising young compared to composites comprising old cells did not vary significantly due to cryopreservation and revitalisation, or because of syngeneic rather than autologous grafting.

Alkaline phosphatase activity was also seen to vary between composites comprising either young or old cells. Composites comprising young cells had 4-6 fold the alkaline phosphatase activity of old cell composites. Similar to the osteocalcin study, no significant change to this ratio was brought about by cryopreservation of cells prior to forming the composites; or from syngeneic grafting rather than autografting.

Table 1 below discloses the ratios of osteocalcin expression seen between the different groups:

Table 1

Group x/Group y	Ratio
1a/1b	1.3
1a/1c	1.4
1a/1d	1.5
2a/2b	0.9
2a/2c	1.4
2a/2d	1.6
3a/3b	1.0

- 38 -

	3a/3c	1.0
	4a/4b	1.3
	4a/4c	0.9
	1a/2a	9.7
5	3a/4a	9.8
	1a/3a	1.4
	2a/4a	1.4

10 Table 2 below discloses the ratios of alkaline phosphatase expression seen between the different groups:

Table 2

15	Group x/Group y	Ratio
	1a/1b	1.1
	1a/1c	1.3
	1a/1d	1.3
20	2a/2b	1.3
	2a/2c	1.5
	2a/2d	1.8
	3a/3b	1.1
	3a/3c	0.9
25	4a/4b	1.3
	4a/4c	0.9
	1a/2a	5.8
	3a/4a	5.9
	1a/3a	1.1
30	2a/4a	1.1

Similar differences in bone forming ability, and in bone gla protein and alkaline phosphatase activity, between marrow cells from young and old rats has been reported
 35 independently by Inoue et al (1997) using syngeneic rats. However, Inoue et al have not reported the effects of cryopreservation on the osteogenic ability of

- 39 -

young and old cells, and whether this clear difference in young and old cell osteogenic ability holds true for autogenous grafts.

5 Example 5

Autologous grafting of neural cells to adult rats

Adult rats at 3 months of age were placed in a
10 stereotaxic frame, and the area of skull overlying the
 lateral ventricle at the level of bregma was removed. A
 blunt-ended, sterile glass micropipette (ID = 100 μ m)
 was inserted into the brain 1.4 mm lateral to the
 midline. The pipette was lowered into the dorsal part
15 of the lateral ventricle at which point, with controlled
 suction, a small amount of cerebrospinal fluid (CSF) was
 withdrawn. Still with controlled suction, the pipette
 was further lowered so that it passed through the
 ventricular, subventricular and other layers of neural
20 tissue situated each side of the lateral ventricle. A
 suspension of tissue, cells and CSF collected in the
 large diameter part of the pipette. At the end of the
 biopsy, the suspension was triturated (sometimes with
 prior enzymatic digestion with eg. trypsin) and ejected
25 into a small tissue culture flask containing medium.
 Such medium comprised a mixture of Dulbecco's modified
 Eagle's medium and Ham's F12 (50/50 v/v) supplemented
 with L-glutamine (2mM), penicillin:streptomycin (100
 IU/ml: 10 mg/ml) and modified stock solution (PNAS USA
30 76(1979)514; J Neurophysiol 40(1981)1132) containing 10
 ng/ml epidermal growth factor (EGF), 5 ng/ml basic
 fibroblast growth factor (FGF), or the like. Sometimes,
 transmembrane co-culture with replicative neural cells,
 or conditioned medium from such cells was also used to
35 support the survival of the newly-dissociated adult
 cells.

- 40 -

The clusters of replicating cells were expanded, and "passaged" by sectioning into 4 - 6 parts followed by replating. This allowed prolonged expansion. Cell clusters, or mechanically dissociated cells derived from them, were frozen either at this stage, or after differentiation (vide infra), in medium containing 10% DMSO and using conventional methods. They were then placed in gas/liquid phase nitrogen followed by prolonged storage in gas/liquid phase helium for periods of up to or including one year.

Thawed frozen replicative cells, or cells from dissociated replicative clusters were replated in roller tubes and allowed to differentiate in the same medium, but without EGF, for the next few days. Some cells were differentiated in the presence of medium conditioned with confluent (but still replicative) striatal cells to provide both support and differentiation-directing/inducing factors. Thereafter, the resulting differentiated cell clusters (approximately 1 million cells) were injected into the original donor rats lesioned 10 days earlier unilaterally by intrastriatal injection of ibotenic acid. Alternatively, the cells were frozen as described above, and then thawed and injected into the lesioned striatum. Three months later the animals were fixed by perfusion, and the grafts analyzed by immunohistochemistry.

Surviving transplants were found in all grafted animals. The implants were well integrated into the host striatum, although they could still be clearly demarcated as an area through which myelinated fibre bundles mostly failed to grow. The proportion of surviving grafts was not affected by whether the donor cells had been frozen at any stage. Indeed, those animals with cells that had been through a freezing procedure possessed larger grafts than non-frozen cells,

- 41 -

and the expression of neurofilament in such grafted cells also appeared to be more intense and extensive. Similarly, some GFAP expression could be seen in the graft.

Example 6

Effects of storage temperature on cell viability after one year

Duplicate aliquots of the cells of the type shown were frozen by methods described in the text, and at the end of 1 hour of cooling at 1°C per minute were placed in liquid nitrogen for 1 hour. At that time, one of each pair of aliquots was thawed by the methods described in the text, and analyzed for cell viability using ethidium bromide exclusion/acridine orange incorporation (Brain Res 331 (1985) 251). The other aliquot was placed in liquid helium for approximately one year, and then thawed and cell viability assessed by the same process. The results are shown in Table 3 below. Figures are the means and SEM of 6 sample pairs, and are expressed as a proportion of the cells surviving after 1 hour in liquid nitrogen. It will be seen that the lower temperature can lead to a small but significant enhancement of the viability of the cells in the long term.

Table 3

Cell type	Storage condition	
	Liquid nitrogen	Liquid helium
Human neural cell line	90.17±1.64	97.55±0.43
Human white cells	87.61±2.38	96.90±0.92
Human marrow stromal cells	89.85±1.39	97.13±0.77

- 42 -

Example 7Effects of storage temperature on cell viability after two years

The "one year" study of Example 6 was repeated, storing an aliquot of cells in liquid helium for 2 years. The cells were then thawed and cell viability was assessed as described in Example 6. The results are shown in Table 4. Figures are the means and SEM of 6 sample pairs, and are expressed as a proportion of the cells surviving after 1 hour in liquid nitrogen. It will be seen that, after two years storage similarly good viability results may be obtained.

Table 4

Cell type	Liquid nitrogen	Liquid helium
Human neural cell line	89.28±2.51	97.08±1.32
Human white cells	88.19±0.96	96.98±1.41
Human marrow stromal cells	86.20±1.67	97.56±0.93

- 43 -

Claims

1. Use of a host cell population of mature, healthy lymphocyte cells obtained from blood of a non-diseased host organism for the preparation of a cell composition for use in subsequent autologous therapeutic transplantation therapy of a disease or disorder of said host organism, wherein the cells are obtained from the host organism before the disease or disorder develops or manifests itself.

2. A method of autologous therapeutic transplantation therapy of a disease or disorder of a host organism, said method comprising transplanting a host organism with a cell composition prepared from a host cell population of mature, healthy lymphocyte cells obtained from blood of said host organism when non-diseased, wherein the cells are obtained from the host organism before the disease or disorder develops or manifests itself.

3. A composition comprising a host cell population of mature healthy lymphocyte cells obtained from blood of a non-diseased host organism for use in subsequent autologous therapeutic transplantation therapy of a disease or disorder of said host organism, wherein the cells are obtained from the host organism before the disease or disorder develops or manifests itself.

4. A use, method or composition as claimed in any one of claims 1 to 3, wherein said host cells are harvested from said host organism at a stage when there is no direct prediction, suggestion or suspicion that said disease or disorder may develop.

5. A use, method or composition as claimed in any one of claims 1 to 4, wherein said host organism is a human.

- 44 -

6. A use, method or composition as claimed in any one of claims 1 to 5, wherein said host organism is juvenile, adolescent or adult, at the time the cells are obtained.
- 5
7. A use, method or composition as claimed in any one of claims 1 to 6, wherein the immune system of said host organism is mature, at the time the cells are obtained.
- 10
8. A use, method or composition as claimed in any one of claims 1 to 7, wherein the immune system of said host organism is uncompromised, at the time the cells are obtained.
- 15
9. A use, method or composition as claimed in any one of claims 1 to 8, wherein said lymphocyte cells are T-lymphocyte cells.
- 20
10. A use, method or composition as claimed in any one of claims 1 to 9, wherein said therapy is therapy of a chronic condition.
- 25
11. A use, method or composition as claimed in any one of claims 1 to 9, wherein said therapy is cancer therapy.
- 30
12. A use, method or composition as claimed in any one of claims 1 to 9, wherein said therapy is for HIV infection or AIDS.
- 35
13. A use, method or composition as claimed in claim 12, wherein said host cell population comprises CD4⁺ cells.
14. A use, method or composition as claimed in any one of claims 1 to 13, wherein said host cell population is maintained in a state of dormancy.

- 45 -

15. A use, method or composition as claimed in any one of claims 1 to 14, wherein said host cell population comprises a genetically modified cell.
- 5 16. A use, method or composition as claimed in any one of claims 1 to 15 wherein, after removal from the host and before transplantation, said host cell population is stored by freezing the cells.
- 10 17. A method of making and/or maintaining lymphocyte cells dormant, said method comprising freezing said lymphocyte cells to a temperature at or below -269°C .
- 15 18. A method as claimed in claim 17 wherein said lymphocyte cells are obtained from blood.
19. A method as claimed in claim 17 or claim 18 wherein said lymphocyte cells are T-lymphocyte cells.
- 20 20. A dormant lymphocyte cell population obtained by the method of any one of claims 17 to 19.

ABSTRACT OF THE DISCLOSURE

The present invention provides use of a host cell population obtained from a non-diseased host organism for the preparation of a cell-composition for use in subsequent autologous transplantation therapy of said host organism.

09/831371 PCT/PTO 1 6 MAY 2001

1/3

Fig.1

**Protection from effects of X-irradiation using
cryopreserved autologous white cells**





Fig.2


Presence of hygromycin resistance gene in rats with autologous grafts of genetically engineered T-lymphocytes



3/3

Fig.3

Presence of hygromycin resistance gene in rats with autologous grafts of T-lymphocytes genetically engineered after cryopreservation



ATTORNEY/DOCKET NO: DAV13002/REF

DECLARATION FOR PATENT APPLICATION AND APPOINTMENT OF ATTORNEY

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name; I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention (Design, if applicable) entitled:

CELLS, CULTURE METHODS, AND THEIR USE IN AUTOLOGOUS TRANSPLANTATION THERAPY

the specification of which (check one):

☐ is attached hereto, or ☒ was filed on: 16 November 1999 as PCT International Application Number: PCT/GB99/03813

and (if applicable) was amended on:

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment(s) referred to above. I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56. I hereby claim foreign priority benefits under Title 35, United States Code §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

PRIORITY FOREIGN APPLICATION(S)			PRIORITY CLAIMED	
Number	Country	Day/Month/Year Filed	Yes	No
9825096.2	GB	16 November 1998	X	

☐ Additional Priority Application(s) Listed on Following Page(s)

I HEREBY CLAIM THE BENEFIT UNDER TITLE 35 U.S. CODE §119(e) OF ANY U.S. PROVISIONAL APPLICATIONS LISTED BELOW.	
Application Number	Day/Month/Year Filed

☐ Additional Provisional Application(s) Listed on Following Page(s)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT International application(s) designating The United States or America listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application(s) and the national or PCT International filing date of this application:

Application Number	Filing Date	Status - Patented, Pending or Abandoned

☐ Additional US/PCT Priority Application(s) listed on Following Page(s)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: I (We) hereby appoint as my (our) attorneys, with full powers of substitution and revocation, to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: J. Ernest Kearney, Reg. No. 19,179; Eugene Mar, Reg. No. 25,893; Richard E. Fichter, Reg. No. 26,382; Thomas J. Moore, Reg. No. 28,974; Joseph DeBenedictis, Reg. No. 23,503; Benjamin E. Ueda, Reg. No. 33,805; and

I (we) authorize my(our) attorneys to accept and follow instructions from FRANK B. DEHN & CO. regarding any matter related to the preparation, examination, grant and maintenance of this application, any continuation, continuation-in-part or divisional based thereon, and any patent resulting therefrom, until I (we) or my(our) assigns withdraw this authorization in writing.

Send correspondence to:

BACON & THOMAS
435 State Lane - 4th Floor
Alexandria, VA 22314-1176

Telephone Calls to: (703) 683-0500

FULL NAME OF FIRST OR SOLE INVENTOR Alison DAVIES	CITIZENSHIP British
RESIDENCE ADDRESS Bevos Farm, Tyngsboro Fordingham CP32 0ND ENGLAND, U.K.	POST OFFICE ADDRESS IS THE SAME AS RESIDENCE ADDRESS UNLESS OTHERWISE SHOWN BELOW
DATE 15/5/01	SIGNATURE Alison Davies

☐ See following page(s) for additional joint inventors.

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☒ *Scanned copy is best available.*

Drawing.